Ipsogen SA Company Profile

03:54 EDT 22nd June 2018 | BioPortfolio

News Articles [3 Associated News Articles listed on BioPortfolio]

FDA Approves First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms

Hilden, Germany, and Germantown, Maryland, January 23, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (i...

QIAGEN erhält FDA-Freigabe für ersten JAK2-Test als Diagnostikum für zusätzliche myeloproliferative Neoplasien

Hilden, Deutschland, und Germantown, Maryland (USA) (ots) - Der erweiterte Anwendungsbereich des ipsogen-Tests erfüllt die diagnostischen Testanforderungen der aktuellen WHO-Leitlinien für alle mye....

FDA clears expanded use of Qiagen's myeloproliferative neoplasm assay

Qiagen's Ipsogen JAK2 RGQ PCR Kit was cleared by the FDA for diagnosing two more types of myeloproliferative neoplasms, namel -More- 

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Ipsogen, Inc

Ipsogen foresees cancer, the second leading cause of death in developed countries, as a unique domain where drug development, commercialisation and prescription can benefit from biomarker discovery, v...

Ipsogen SA

More Information about "Ipsogen SA" on BioPortfolio

We have published hundreds of Ipsogen SA news stories on BioPortfolio along with dozens of Ipsogen SA Clinical Trials and PubMed Articles about Ipsogen SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ipsogen SA Companies in our database. You can also find out about relevant Ipsogen SA Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record